David Backer
About
David Backer is from Carlsbad, California, United States. David is currently Strategic Advisor for CMC at Rett Syndrome Research Trust. David also works as Commercial Adviser at Lentitek, a job David has held since Jun 2024. Another title David currently holds is Principal and Consultant at DB Biologics LLC. In David's previous role as a Board Advisor at Matica Biotechnology, Inc., David worked in until Mar 2025. Prior to joining Matica Biotechnology, Inc., David was a Chief Executive Officer at Curate Biosciences and held the position of Chief Executive Officer at Carlsbad, California, United States. Prior to that, David was a Chief Commercial Officer at Oxford Biomedica from Sep 2021 to Aug 2022. David started working as SVP, Commercial Development at ElevateBio in Greater Boston Area in Apr 2019. From Sep 2016 to Mar 2019, David was Head of Commercial Development, Gene Editing and Novel Modalities at MilliporeSigma, based in Carlsbad, CA. Prior to that, David was a Global VP, Virus and Gene Therapy Services at SAFC from Aug 2015 to Sep 2016. David started working as Sr. Director and General Manager at SAFC in Carlsbad, CA in Aug 2012.
Go to finalscout.com and type David Backer's name into the search box for a free email address. FinalScout is a professional database with more than 500 million business professionals and 200 million company executives.
David Backer's current jobs
DB Biologics provides strategy and CMC support for Cell and Gene therapy companies, utilizing sales, marketing, strategy, operational, and general management experience. Clients include Innovator companies, CDMOs, and tools companies.
David Backer's past jobs
At Curate Biosciences we see a future where patients, clinicians, innovators, and payors routinely embrace cell and gene therapies against intractable disease. We foresee a world in which life-saving therapies are readily accessible to all, earlier in the treatment protocol, with longer persistence, fewer side effects, and with a positive impact to healthcare economics. To help make this future a reality, we focus on advancing our platform technology, Deterministic Cell Separation™, to deliver greater quantities of the highest quality cellular starting materials, faster and less costly, to the innovators, developers, and clinicians pushing the boundaries of the possible.
Led the Business Development and commercial support for the Gene Editing and Novel Modalities group, which comprises of researchers, marketing, and commercial development specialists in the areas of gene editing, cell based assays for discovery and toxicology, cell therapy applications, and gene therapy applications.
Responsible for P&L at SAFC's Carlsbad site. Substantial increase in revenue and improvement of profitability in first year.
SAFC Pharma (formerly Molecular Medicine BioServices) is a contract manufacturing organization (CMO), specializing in the scaleup and cGMP manufacturing of viral vaccines and viral gene therapeutics. Based in Carlsbad, CA, the company was bought from Roche and UCSD in 2001 and sold to Sigma-Aldrich in 2007.
Became President of Molecular Medicine, LLC in May, 2001. Successfully acquired company via Management buyout in September, 2001. Sold company to Sigma-Aldrich in May, 2007